Результаты поиска

Atorvastatin inhibits osteoclastogenesis and arrests tooth movement.

INTRODUCTION: In addition to their cholesterol-lowering effects, the statin class of drugs appears to enhance osteogenesis and suppress bone resorption, which could be a clinical concern during orthodontic treatment. In this animal study, we aimed to determine whether atorvastatin (ATV) affects orthodontic tooth movement (OTM) through osteoclast inhibition. Furthermore, we analyzed the potential adverse effects of ATV on long-bone turnover and endochondral ossification. METHODS: Rats were administered ATV (15 mg/kg) or saline solution via gavage (n = 12 animals/group), starting 2 weeks before…

Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse.

INTRODUCTION: The statin class of drugs enhances osteogenesis and suppresses bone resorption, which could be a plausible biologic mechanism for mitigation of orthodontic relapse. We aimed to determine whether atorvastatin (ATV) might affect orthodontic relapse and osteoclastogenesis by modulating expression of RANKL and osteoprotegerin (OPG), crucial molecules involved in bone turnover. Furthermore, we analyzed the adverse effects of ATV on femur turnover and endochondral ossification. METHODS: Wistar rats were subjected to orthodontic tooth movement for 21 days, followed by removal of the ap…

Pemphigus erythematosus relapse associated with atorvastatin intake.

Statins, also known as 3-hydroxy-3-methylglutaril-CoA reductase inhibitors, are well-tolerated drugs used for prevention of atherosclerosis … pemphigus erythematosus, a syndrome with features of both lupus erythematosus and pemphigus, after atorvastatin intake.

Atorvastatin in pulmonary arterial hypertension (APATH) study.

Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corre…

Atorvastatin-induced hemorrhagic cystitis: a case report.

The first case of hemorrhagic cystitis due to atorvastatin for treatment of hyperlipidemia is reported. Hematuria resolved spontaneously with discontinuation of the drug.

Golf-inhibiting gynecomastia associated with atorvastatin therapy.

Gynecomastia can have a significant emotional and social impact on men. Although numerous drug therapies may cause this condition, we found no documented cases of gynecomastia associated with atorvastatin. We describe the development of breast enlargement and tenderness in a 52-year-old Caucasian man 6 months after his simvastatin therapy had been switched to atorvastatin. His symptoms ultimately interfered with his ability to play golf and participate in other activities. These problems resolved after atorvastatin discontinuation and did not recur despite resumption of simvastatin therapy. Th…

Обобщение и оценка воздействия нанопчастей аторвастатина и аторвастатина на вызванную ими демиелинацию Cuprizone: модуляция прохода с сигналами Nrf2/NF-kB.

Множественный склероз (MS) является хроническим воспалительным заболеванием центральной нервной системы (CNS), характеризующимся повреждением миелинской оболочки и, со временем, постепенным неврологическим расстройством. Статины привлекли внимание к исследованиям в области MS из-за их антивоспалительных и нейрозащитных эффектов. ЦЕЛИ: В этом исследовании оценивалось, может ли аторвастатин улучшить поведение и гистопатологические изменения мозга мужчины C57BL/6 Мыши. Все группы мышей, за исключением контрольной группы, которая получила нормальное питание, были накормлены 0.2% (КПЗ) в их ежеднев

Совпадение в аннотации оригинала
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) characterized by damage to the mye … ng to their anti-inflammatory and neuroprotective effects. OBJECTIVES: This study assessed whether atorvastatin could ameliorate cuprizone-induced behavioral and histopathological changes in the brains of male C57BL/6 mice. METHODS: All groups of mice, except the control group, which received a normal diet, were fed 0.2% cuprizone (CPZ) in their daily diet f …

Atorvastatin and ischemic stroke: Mechanisms and therapeutic applications.

Stroke is a leading cause of death and disability, affecting approximately 13.7 million people worldwide and causing 5.5 million deaths annually. Effective treatment options for ischemic stroke are still limited and existing clinical interventions have limitations such as the time window for treatment. Therefore, research is needed to find complementary therapies that can reduce the complications of stroke or prevent its occurrence. Atorvastatin is an oral medication used to lower lipid levels via competitive inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, which results in d…

The potential of Atorvastatin for chronic lung diseases therapy.

Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase thus leading to a reduction in cholesterol synthesis. It has recently been demonstrated that ATO has different pharmacological actions, which are unrelated to its lipid-lowering effects and has the ability to treat chronic airway diseases. This paper reviews the potential of ATO as an anti-inflammatory, antioxidant, and anti-proliferative agent after oral or inhaled administration. This pa…

The Concomitant Use of Atorvastatin and Amlodipine Leading to Rhabdomyolysis.

A 65-year-old man, with a history of hypertension and hyperlipidemia, presented with intractable lower back pain, shortness of breath, and decreasing urine output at the emergency room and was admitted after he was found to have elevated creatinine kinase levels of greater than 160,000 U/L. We discontinued all his home medications, which included atorvastatin and amlodipine. We trended his creatine phosphokinase (CPK) level daily and noticed it decreasing significantly off these meds. We hydrated him with normal saline and monitored his kidney functions. By the time he was ready for discharge,…

Atorvastatin calcium plus amlodipine for the treatment of hypertension.

INTRODUCTION: Hypertension (HTN) and dyslipemia (DYL) are two of the major modifiable cardiovascular (CV) risk factors, determinants in the … antihypertensive and a lipid-lowering agent, the single-pill combination of amlodipine besylate and atorvastatin calcium (SPAA). They summarize the pharmacokinetic and pharmacodynamic properties of both compounds and the main randomized clinical studies, as well as real-world observational studies, made with the new combined formulation. EXPERT OPINION: The u …

Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.

BACKGROUND: Recent data indicate that statins could offer coronary artery disease (CAD) benefit even by mechanisms beyond lipid lowering. Ge … A prospective 4-year study involving 1039 event-free subjects (643 males, 396 females) treated with atorvastatin (10-40 mg day(-1)) to reach the appropriate Adult Treatment Panel-III LDL target of 3.36 mmol L(-1). Enrolled subjects were evaluated every 6 months or at a clinical event. LOX-1 3'UTR/T-C and NOS G894T polymorphisms were detected by allelic discrim …

Atorvastatin in prevention of stroke and transient ischaemic attack.

Besides blood pressure-lowering drugs and, in certain circumstances, antithrombotic agents, statins are among the most effective drugs in reducing the risk of stroke in populations of patients at high vascular risk, as well as the risk of major coronary events. In secondary prevention of stroke, statins clearly reduced the risk of major coronary events. In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, compared with placebo, the patients with a recent stroke or transient ischaemic attack without coronary heart disease randomised to atorvastatin 80 mg/day ha…

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.

BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gradually progress to cirrhosis. It is generally associated with obesity, diabetes and hyperlipidemia. Currently, there is no established therapy for NASH. The aim of the present study was to evaluate the effectiveness of atorvastatin and ursodeoxycholic acid (UDCA) in the treatment of NASH. METHODS: This prospective study included 44 adult patients (24 men, 20 women) with a mean age of 48.90+/-7.69 years and mean body mass index (BMI) of 29.40+/-3.82. Ten patients had a history of diabetes. Serol…

[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].

Atorvastatin, commercialized by the pharmaceutical companies Parke-Davis and Pfizer under the trade name Lipitor, is a new statin acting as a potent hypolipidaemic drug. By inhibiting HMG-CoA reductase, the key-enzyme of cellular synthesis of cholesterol, it increases the expression of LDL receptors and promotes the hepatic extraction of circulating LDL. It has a more potent action than other available statins, both on LDL cholesterol and triglyceride levels. Atorvastatin is indicated, after diet failure, in the treatment of primary hypercholesterolaemia or combined hyperlipidaemia. Lipitor is…

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge.

BACKGROUND: Statin-induced liver injury is frequent and usually not severe. The aim of the present study was to describe the safety of statin rechallenge after atorvastatin-induced liver injury because it is poorly documented. METHODS: Cases of liver injury involving atorvastatin were selected from the French pharmacovigilance database. Inclusion criteria were a documented atorvastatin or any other statin reintroduction and an available follow-up of at least 2 weeks to define negative rechallenge. RESULTS: Twenty-six cases of atorvastatin liver injury with further statin reintroduction met o…

Atorvastatin-induced Myositis and Drug-induced Liver Injury.

Statins are drugs for preventing cardiac events in the elderly population. Statins are well tolerated with a lower reported incidence of ser … antly improved with prompt management. How to cite this article: Kashyap K, Bisht K, Dhar M, et al. Atorvastatin-induced Myositis and Drug-induced Liver Injury. J Assoc Physicians India 2023;71(10):96-98.

Atorvastatin efficiency after traumatic brain injury in rats.

BACKGROUND: The neuroprotective effects of statins possibly depend on their pleiotropic effect such as antioxidative and anti-inflammatory properties. In this study, we have evaluated the efficiency of atorvastatin on brain edema, lipid peroxidation, and ultrastructural changes in TBI animal model. METHODS: Modified Feeney method has been used for the trauma model in rats. Only craniectomy for group A and trauma after craniectomy for group B was the procedure for animals. For the trauma, rods weighing 24 g were dropped on a foot plate just over the dura. Atorvastatin (1 mg/kg, IP) was adminis…